InvestDashboard.com



Dicerna Pharmaceuticals, Inc. (DRNA)



$2.42
52 Week Low
$3.33
2017-04-28 14:17:06 MDT
$6.1
52 Week High

Basic Info

Healthcare
Sector
Biotechnology
Industry
Nasdaq
Stock Exchange
United States
Country

Market Cap: $61,970,000Micro Cap (Less than $200M)
Analyst Recommendation:2Analysts say: Buy. (1=Strong Buy, 5=Strong Sell)
Beta: 2.48 Higher Volatility Stock (beta over 1). Stock will go up more when the market goes up, and go down more when the market goes down. Beta of 1 means stock would match the S&P 500 Index.

Fundamentals

ForwardPE: Unknown
5 Yr Est Growth: Unknown
Yield: 0.00%
PEG-Y Ratio: N/A
Unknown PEG-Y ratio

Technicals

% Above 50 DayMA: 11.74%
% Above 200 DayMA: 4.72%
DRNA Performance 52 Weeks: -39.63%
S&P 500 Performance 52 Weeks: 12.50%
Uptrend is still intact: DRNA is above both 50 and 200 day Moving Averages. Currently beyond technical death cross because 50 Day MA is below 200 Day MA. Stock is closer to 52 Week Low than 52 Week High.
DRNA underperforming S&P 500 by -52.13% the last 52 Weeks.

Profile


More Valuation

Price To Book: 1.48
Great Value. Low Price to Book means better value.
EV to EBITDA: -0.26
Unknown EV to EBITDA ratio

More Info

Field Value Average Comments
% Held By Insiders18.25% 17.28%Held by greater than average Insiders. Insiders can sway stock price. Watch insider buying and selling.
% Held By Institutions74.60% 62.07%Institutional percentage greater than average. Institutional buying and selling can really move stock price.
Short % Of Float1.51% 07.02% Shorted percentage less than average percent. Is stock loved? Do traders and investors believe in the stock?
Debt to EquityN/A 1.08Unknown.
Profit Margin %N/A-00.18%Unknown.
Operating Margin %-20.00%-05.28% Operating Margin less than average percent. Stock can do better than this?
Return on Equity %-90.01%-08.79% Return on Equity less than average percent. Stock can do better than this?
Return on Assets %-49.37%-01.29% Return on Assets less than average percent. Stock can do better than this?
Revenue Per Employee $6,276.60 $883,096.70 Less than average Revenue Per Employee. This stock (or industry) might not be as efficient as others? Each industry might have a different standard.
Price to Cash 1.51 5.52 Lower than average Price to Cash. Meaning that the company has a higher percentage of cash as a percent of price. Cash can be good to cushion company during hard times, and as a potential source for buyouts or investments. However, some activists want the cash to be used by a company to buy its own stock, or to increase their dividend, or to invest the money.
CPEGY Ratio N/A 2.26Unknown.

Quick Thoughts

PROS:
  1. Analysts like this stock: 2 (1=Strong Buy, 5=Strong Sell)

  2. Stock is Above Short Term 50DMA: 11.74%

  3. Stock is Above Long Term 200DMA: 4.72%

  4. Price to Cash Ratio (1.51) is less than average. Good. Company has more cash as percentage of price than other companies.

  5. Price to Book is under 5: 1.48

  6. Shorted less than average: 1.51%

CONS:
  1. Stock underperforming S&P 500 over last 52 weeks: -52.13%

  2. Operating Margin is negative: -20.00%

  3. Return on Equity is negative: -90.01%

  4. Return on Assets is negative: -49.37%


Headlines


Stock Chart


InvestDashboard.com DRNA: Dicerna Pharmaceuticals, Inc.

This page updated Thu Feb 1 22:00:01 MST 2018.